Congress removes tax penalty for sick people joining drug trials

What it does

This bill excludes compensation paid to people who participate in clinical trials from their taxable income and shields that income from counting against eligibility for federal assistance programs like Medicaid, SNAP, or housing aid. It applies to both direct payments for participation and reimbursement of trial-related expenses, effective for payments after December 31, 2025.

Why we flagged it

The bill's core function is straightforward: it creates a tax exclusion for clinical trial compensation and shields that income from means-testing for federal benefits. This is a targeted tax relief measure aimed at removing barriers to trial participation.

What the text implies

• Pharmaceutical and biotech companies may see increased trial enrollment, particularly among low-income and uninsured populations who previously avoided trials due to benefit loss—a material benefit to trial recruitment without explicit subsidy.
• The provision may disproportionately benefit large-scale, well-funded trials (typically run by major pharma) over small academic or rare-disease trials with smaller participant pools and lower compensation.
• State Medicaid programs and other means-tested benefit administrators will need to implement new income-exclusion rules, creating administrative burden and potential inconsistency in application across states.
• The bill does not cap trial compensation amounts, meaning high-paying trials (e.g., Phase I safety studies) could result in substantial tax-free income for participants without triggering benefit loss—a potential loophole for wealthy participants in high-paying trials.

Who it affects

Clinical trial participants—often people with serious illnesses seeking new treatments—gain tax relief and retain access to safety-net benefits they may depend on. The bill removes a perverse incentive that currently penalizes sick people for seeking experimental treatments. Low-income participants benefit most, as they are most likely to lose benefits due to trial income.

Who stands to gain

• pharmaceutical companies (trial recruitment cost reduction)
• biotech firms (improved trial enrollment)
• contract research organizations (CROs)
• clinical trial management companies

Named in the bill

Internal Revenue Code of 1986, Public Health Service Act (42 U.S.C. 300gg–8), Section 139J (new), Section 2709 (approved clinical trial definition), Federal assistance programs (Medicaid, SNAP, housing), State and local programs financed with federal funds, Bristol Myers Squibb (BMY), Guardant Health (GH), Pfizer (PFE), DaVita (DVA), Johnson & Johnson (JNJ)

Where it stands

1 cosponsor: 1 Democrats.

• Jun 26, 2025 — Introduced · Congress.gov: “Introduced in House”
• Jun 26, 2025 — Referred to House Committee on Ways and Means · Congress.gov: “Referred to the House Committee on Ways and Means”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

4 lobbying clients named this bill on 7 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $3,860,000 in lobbying spend. A filing names 7 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 72% of bills with at least one filing.

Mike Kelly, the sponsor, reported $955,974 in PAC receipts in the 2026 cycle.

• American Cancer Society Cancer Action Network Inc — $3,620,000 on 2 filings
• Columbia University — $100,000 on 2 filings
• Mural Health — $100,000 on 2 filings
• Patient Access Network Foundation — $40,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.